Hospitals across the Capital maintained that they have revised and are offering the new, low-priced stents rates as per direction of the National Pharmaceutical Pricing Authority (NPPA) which came in earlier this month. Cardiologists have welcomed the lowered-price list stating that the benefit will be seen immediately.
While the National Pharmaceutical Pricing Authority (NPPA) revised the ceiling price on coronary stents on Monday, its Chairman Bhupendra Singh stated on Friday that that the price control is not the best option to achieve affordability. “If you ask me, I don’t consider that price control is the best option to achieve affordability.
After price caps on cardiac stents and knee implants, a cap is now eagerly awaited on hip implants, which too are highly priced due to excessive profiteering by manufacturers, distributors as well as healthcare providers. “The price control on all implants has been widely discussed.